Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy.
about
Use of germicides in the home and the healthcare setting: is there a relationship between germicide use and antibiotic resistance?Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitisFitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.Factors associated with ceftriaxone nonsusceptibility of Streptococcus pneumoniae: analysis of South African national surveillance data, 2003 to 2010.Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae.Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumoniaContributions of pneumolysin, pneumococcal surface protein A (PspA), and PspC to pathogenicity of Streptococcus pneumoniae D39 in a mouse model.Update on the clinical utility and optimal use of cefditorenQuality measures for the care of children with otitis media with effusion.Tigecycline versus levofloxacin in hospitalized patients with community-acquired pneumonia: an analysis of risk factors.Increasing penicillin and trimethoprim-sulfamethoxazole resistance in nasopharyngeal Streptococcus pneumoniae isolates from Guatemalan children, 2001--2006.Controversies in the treatment of pneumococcal community-acquired pneumonia.In vitro activity of Iclaprim against respiratory and bacteremic isolates of Streptococcus pneumoniae.A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae.Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality.Antimicrobial resistance among Gram-positive pathogens in Saudi Arabia.Cotrimoxazole resistance of Streptococcus pneumoniae and commensal streptococci from Kampala, Uganda.Dentures are a Reservoir for Respiratory Pathogens.Advances in pneumococcal antibiotic resistance.Community-acquired pneumonia in North American emergency departments: drug resistance and treatment success with clarithromycin.Risk factors for 30-day mortality in adult patients with pneumococcal bacteraemia, and the impact of antimicrobial resistance on clinical outcomes.In silico study on Penicillin derivatives and Cephalosporins for upper respiratory tract bacterial pathogens.Narrowing in on JCAHO Recommendations for Community-acquired PneumoniaInsights into the antibacterial mechanism of PEGylated nano-bacitracin A against : both penicillin-sensitive and penicillin-resistant strains
P2860
Q28265803-141A5CB2-7409-42C5-B387-28698755C899Q28757559-DCE2BA5C-5FBB-42B6-A3FF-640A69877593Q33264145-F871AAFD-5E03-468E-91CA-3415FDE4BF58Q33798133-FFDB1F42-EA51-4CF5-A56E-731E877809AEQ35689099-0CE5B2A2-5F63-4592-9B2B-28C3E4A1405BQ35752997-B404ABCE-E5FE-4929-9F60-20EF3E673016Q35783885-2837C314-8EA1-4DC5-9651-94FBDA1B8BB9Q36008860-FD97F0D7-3446-4602-82DD-C268361DDB03Q36071131-09F6E4FF-8A53-4B36-A3F1-991AA928B0BAQ36695534-009EFC9F-62E9-4405-87B9-CD660F4D5AE4Q36726907-19A57EF8-D702-456F-85E9-D8F8BE842190Q36895630-372663E8-198B-4219-9498-96ACF36F3510Q37144800-4647CBE6-EA17-4108-86C6-57423FE22569Q37333825-468404B4-16AD-41E3-8C00-58135C495514Q37870823-C3CB18A8-30E7-4652-80B3-E46BB1ED78BCQ38023661-661D9A55-0701-450E-973E-7FE1899221DDQ38875026-47EB7DD0-7B97-4C75-BF80-4FBBD0B10176Q41060301-FFCBF9FA-686B-4BA2-B942-E5D6BE63D07CQ42243746-78427322-45B7-447C-AD63-3AF7BD8DEAEDQ44461718-7D22BFAF-9F92-45A8-92A1-BA703D921F16Q51009546-51DBB602-4659-4358-AC86-B7E05667B9C8Q55443184-39FB5755-8EFE-4327-BFA1-C62C35186DEEQ57432744-0F5BDE93-50DB-4F24-A062-42EA62D1B4DDQ57816229-DAF00704-2612-42CC-854A-1EA71DB65C1F
P2860
Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Escalation of antimicrobial re ...... iae: implications for therapy.
@ast
Escalation of antimicrobial re ...... iae: implications for therapy.
@en
type
label
Escalation of antimicrobial re ...... iae: implications for therapy.
@ast
Escalation of antimicrobial re ...... iae: implications for therapy.
@en
prefLabel
Escalation of antimicrobial re ...... iae: implications for therapy.
@ast
Escalation of antimicrobial re ...... iae: implications for therapy.
@en
P356
P1476
Escalation of antimicrobial re ...... iae: implications for therapy.
@en
P2093
Joseph P Lynch
P304
P356
10.1055/S-2005-925524
P577
2005-12-01T00:00:00Z